Diarrhea News and Research

Latest Diarrhea News and Research

Vitamin A supplements could save the lives of 600,000 children a year, researchers say

"Giving vitamin A supplements to children under the age of five in developing countries could save 600,000 lives a year, researchers claim" in a paper published Thursday in the British Medical Journal, BBC News reports.

30 Aug 2011

High risk of serious complications or death in children with SP-HUS

Hemolytic uremic syndrome (HUS) caused by infection with pneumococcal bacteria leads to severe illness—with a high rate of irreversible kidney damage—in infants and young children, reports a study in the September issue of The Pediatric Infectious Disease Journal.

30 Aug 2011

Vitamin A supplements in children could save up to 600,000 lives a year: Study

Researchers have found that giving vitamin A supplements to children under the age of five in developing countries could save up to 600,000 lives a year. Writing in the British Medical Journal, UK and Pakistani experts assessed 43 studies involving 200,000 children, and found deaths were cut by 24% if children were given the vitamin. They add that it would also cut rates of measles and diarrhea.

30 Aug 2011

Pfizer's Xalkori receives FDA approval to treat late-stage NSCLC patients with abnormal ALK gene

The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat certain patients with late-stage (locally advanced or metastatic), non-small cell lung cancers (NSCLC) who express the abnormal anaplastic lymphoma kinase (ALK) gene.

29 Aug 2011

Pfizer receives FDA approval for XALKORI capsules to treat ALK-positive NSCLC

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved XALKORI (crizotinib) capsules, the first-ever therapy targeting anaplastic lymphoma kinase (ALK), for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is ALK-positive as detected by an FDA-approved test.

29 Aug 2011

Protein that allows Ebola virus to attack cells discovered

A U.S. research team has discovered a protein called Niemann-Pick C1 (NPC1), which they found was responsible for allowing Ebola virus to enter and replicate within cells.

26 Aug 2011

Rotavirus vaccine still effective in reducing diarrhea-related deaths in Mexico, researchers say

"The rotavirus vaccine introduced in Mexico in 2007 still appears to be preventing diarrhea-related deaths in children, despite speculation that years later the vaccine may not be as effective," according to the Los Angeles Times' "Booster Shots" blog.

26 Aug 2011

Researchers discover NPC1 protein as crucial for Ebola virus to enter host cells

Although outbreaks are rare, Ebola virus, the cause of Ebola hemorrhagic fever (EHF), is one of the deadliest known viruses affecting humans. According to the World Health Organization (WHO), approximately 1,850 EHF cases with more than 1,200 deaths have been documented since the virus was identified in 1976.

25 Aug 2011

Measles exposure in Philadelphia and Lancaster counties

The Pennsylvania Department of Health and the Philadelphia Department of Public Health are advising the public of exposure to a case of measles in Lancaster and Philadelphia counties.

24 Aug 2011

Bacteria tweak their genes and proteins to gain strength

Scientists have discovered that bacteria like E. coli and Salmonella have a sneaky way of making minor alterations to their genes to boost their chances for infection.

24 Aug 2011

Lack of access to water, sanitation in urban areas contributes to disease, impacts economies, water conference hears

"How best to provide clean water and sanitation to the world's cities and their expanding slums is the overriding theme of World Water Week, which opened Monday in Stockholm," Deutsche Presse-Agentur/M&C reports.

24 Aug 2011

Researchers discover expression of IL-37 that protects mice from colitis

Inflammatory bowel disease (IBD), which affects more than 1 million patients in North America, results from an uncontrolled immune response triggered by environmental factors, such as bacteria, in people genetically predisposed to the disorder. Ulcerative colitis, or inflammation of the lining of the colon, is one such condition.

24 Aug 2011

Hospital acquired Clostridium difficile bug defense system identified

American researchers have discovered the process by which the cells in the gut fight off toxins produced by a hospital bug - Clostridium difficile. Writing in Nature Medicine, they showed how a chemical - GSNO - deactivated a toxin from Clostridium difficile which causes inflammation and diarrhea. They hope to use their findings to develop a treatment for C. difficile.

23 Aug 2011

KU professor to create patient-friendly lung cancer treatment

A Kansas State University professor is trying to create a patient-friendly treatment to help the more than 220,000 people who are diagnosed with lung cancer each year.

23 Aug 2011

Symphogen initiates Sym004 Phase 2 trial in squamous cell carcinoma of head and neck cancer

Symphogen A/S today announced the initiation of a Phase 2 clinical trial to investigate the safety and efficacy of Sym004 in patients who have failed anti-EGFR monoclonal antibody (mAb)-based therapy, with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

23 Aug 2011

Santarus, Depomed enter new commercialization agreement for GLUMETZA

Santarus, Inc. and Depomed, Inc. today announced that they have entered into a new commercialization agreement for GLUMETZA (metformin hydrochloride extended release tablets) under which Santarus will assume broad commercial, manufacturing and regulatory responsibilities to replace a promotion agreement that the companies entered into in July 2008.

23 Aug 2011

Vertex receives Health Canada approval for INCIVEK to treat hepatitis C

Vertex Pharmaceuticals Incorporated today announced that Health Canada has approved INCIVEK tablets for a broad group of people with genotype 1 chronic hepatitis C with compensated liver disease, including cirrhosis.

23 Aug 2011

Research uncovers natural defense mechanism that inactivates C. diff toxins

Groundbreaking research encompassing Case Western Reserve University School of Medicine and University Hospitals Case Medical Center, has uncovered a natural defense mechanism that is capable of inactivating the toxin that spreads Clostridium difficile, or C. diff, an increasingly common bacterial infection in hospitals and long-term care settings.

22 Aug 2011

Scientists discover key defense mechanism against C. difficile infection

Researchers have discovered a key mechanism used by intestinal cells to defend themselves against one of the world's most common hospital-acquired bacterial infections - a mechanism they think they can exploit to produce a therapy to protect against the effects of the antibiotic-resistant bacteria.

22 Aug 2011

New CDI therapeutic approach may offer treatment for other bacterial diseases

Researchers at the David Geffen School of Medicine at UCLA and the University of Texas Medical Branch at Galveston have discovered a molecular process by which the body can defend against the effects of Clostridium difficile infection (CDI), pointing the way to a promising new approach for treating an intestinal disease that has become more common, more severe and harder to cure in recent years.

22 Aug 2011